Snowball logo
logo
BDX_logo

Becton, Dickinson and Company

$181.97-$1.61ย  (0.88%)
BDX has shown a steady increase in revenue, climbi...
View AAPL example
Estimate
P/E
31.5
EPS
5.78
Beta
0.258
Growth
Revenue, YoY
-9.55%
Net income, YoY
-34.32%
FCF, YoY
65.36%
Forecast
P/E (FWD)
13.7
EPS (FWD)
13.33
Dividends
Dividend yield
2.31%
Annual payout
$4.20
Next ex. div date
September 9, 26
Payout
187.14%
Div.growth, 5y
10.26%
Dividend growth streak
42 y
Div.rating
About the company
Ticker
BDX
ISIN
US0758871091
Country
United States of America
Sector (GICS)
Healthcare
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

Frequently asked questions

What sector does Becton, Dickinson and Company (BDX) operate in?

Becton, Dickinson and Company belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is Becton, Dickinson and Company (BDX) current stock price?

As of the latest data, Becton, Dickinson and Company stock price is $181.97, with a previous close of $183.58. Becton, Dickinson and Company lost -$1.61 in the last trading session, representing a -0.88% loss.

What is Becton, Dickinson and Company (BDX) current market capitalization?

Becton, Dickinson and Company market cap is approximately 49.57 billion.

What is Becton, Dickinson and Company (BDX) Earnings Per Share (EPS)?

The trailing EPS is $5.78, and the forward EPS is $13.33.

What is Becton, Dickinson and Company (BDX) Price-to-Earnings (P/E) ratio?

Becton, Dickinson and Company current P/E ratio is 31.48, with a forward P/E of 13.65.

What is Becton, Dickinson and Company (BDX) EBITDA?

Becton, Dickinson and Company EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 686.00 million.

Does Becton, Dickinson and Company (BDX) pay dividends?

Yes. Becton, Dickinson and Company pays quarterly dividends with an annualized yield of 2.31% and an estimated annual payout of $4.20 per share.

When is the next ex-dividend date for Becton, Dickinson and Company (BDX)?

The next ex-dividend date is scheduled for September 09, 2026.

How did Becton, Dickinson and Company (BDX) perform in its most recent earnings report?

In the last report (June 30, 2026), Becton, Dickinson and Company posted an EPS surprise of 2.87% and a revenue surprise of 1.91%.

What is Becton, Dickinson and Company (BDX) beta (volatility) score?

Becton, Dickinson and Company has a beta of 0.258, indicating lower volatility than the overall market.